- 首页
- Cyclooxygenase (COX)
- Revaprazan hydrochloride
Revaprazan hydrochloride
Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥250.00200.00- +
-
10mg￥387.00310.00- +
-
25mg￥875.00700.00- +
-
50mg￥1212.00970.00- +
-
100mg￥1912.001530.00- +
-
200mg￥0.000.00- +
-
500mg￥0.000.00- +
- 货号: ajcx14446
- CAS: 178307-42-1
- 别名: 盐酸瑞伐拉赞
- 分子式: C22H24ClFN4
- 分子量: 398.9
- 纯度: ＞98%
- 溶解度: DMSO: 8.33 mg/mL (20.88 mM)
- 储存: Store at -20°C
- 库存: 现货
Background
Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
Revaprazan Hydrochloride reversibly inhibits H+/K+-ATPase via binding to the K+-binding site of the pump. This reversibility leads to fewer adverse events[1]. Revaprazan could inhibit H.pylori-induced COX-2 expression by blocking phosphorylation of IκB-α and Akt signaling in AGS cells. It could impose significant anti-inflammatory actions on H.pylori infection beyond acid suppression[2].
Pharmacokinetic studies of revaprazan hydrochloride in rats and dogs showed the drug had a low oral bioavailability, which was speculated to be due to first pass effect and poor water solubility of drug[1].
[1] Li W, et al. Int J Pharm. 2011, 408(1-2):157-62. [2] Lee JS, et al. J Clin Biochem Nutr. 2012, 51(2):77-83.
